Cardiology

Armstrong discusses the positive time-to-healing data from the phase 2 LEGenD-1 study, investigating anatomically targeted delivery of AMG0001.

Bristol Myers Squibb has reported positive results from the ongoing SCOUT-HCM trial, demonstrating mavacamten’s efficacy in reducing Valsalva LVOT.

Rosenson explains the data gained from a terminated phase 2b trial, highlighting evinacumab’s potential as a triglyceride-lowering therapy.

The Q4 recap for cardiology spotlights major FDA decisions, key clinical trial updates, and more.

A trio of professional societies voice concerns about certain elements of the Dietary Guidelines for Americans, 2025–2030, and their potential negative health impacts.

Osborne discusses the background behind fenofibrates’ approval for cardiovascular event reduction, despite no evidence supporting their efficacy.

Kohli discusses the importance of the FDA’s recent label change and how clinicians can help reduce the continued prescription of ineffective medication.

Catch up with major FDA decisions, critical conference news, and more.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and CRLs, in this week’s essential news roundup.

Cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the groundbreaking news of oral semaglutide's approval and its cardioprotective benefits.

Catch up on the most impactful headlines in HF from all of 2025 with our Year in Review.

Catch up on the most impactful headlines in cardiology from all of 2025 with our Year in Review.

Catch up on the most impactful headlines in dyslipidemia from all of 2025 with our Year in Review.

The FDA has approved an sNDA for the FUROSCIX On-body Infusor in pediatric patients and accepted another for the FUROSCIX ReadyFlow Autoinjector.

Stay updated with the latest healthcare breakthroughs, including FDA news and phase 3 trial readouts, in this week's essential news roundup.

The approval is based on phase 3 SEQUOIA-HCM clinical trial. The full US Prescribing Information includes a Boxed Warning for the risk of heart failure.

A cross-sectional study indicates a link between urinary levels of measured metals and metalloids and the stages of cardiovascular-kidney-metabolic syndrome.

GLP-1 medications are revolutionizing treatment for neurological conditions.

Kereiakes discusses the potential of lerodalcibep for adults with hypercholesterolemia and high LDL-C, highlighting recent FDA approval.

FDA approves lerodalcibep, a groundbreaking PCSK9 inhibitor, offering a monthly injection for LDL cholesterol reduction in patients with HoFH.

The FDA has approved etripamil nasal spray for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhythm.

Cross-sectional analysis from NHANES shows patients with advanced cardiovascular-kidney-metabolic syndrome are at an increased sarcopenia risk.

Weight-adjusted waist index outperforms obesity indices for cardiovascular disease prediction in cardiovascular-kidney-metabolic syndrome

GLP-1 receptor agonists revolutionize treatment in cardiology, offering new hope for heart failure and related conditions beyond weight loss.

This FDA News Month in Review provides a round-up of regulatory decisions from November 2025.